PMID

Data

Article Title

Organization

RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency.

Aventis Pharma

Non-kinase targets of protein kinase inhibitors.

The University Of Sydney

Synthesis and biological activity of pyridopyridazin-6-one p38a MAP kinase inhibitors. Part 2.

Merck Research Laboratories

Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties.

Eli Lilly

SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.

Novartis Institutes For Biomedical Research

Synthesis and biological activity of 2H-quinolizin-2-one based p38alpha MAP kinase inhibitors.

Merck Research Laboratories

Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.

Novartis Institutes For Biomedical Research

Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.

Novartis Institutes For Biomedical Research

A novel Pd-catalyzed cyclization reaction of ureas for the synthesis of dihydroquinazolinone p38 kinase inhibitors.

Novartis Institute For Biomedical Research

Imidazopyrimidines, potent inhibitors of p38 MAP kinase.

Johnson & Johnson Pharmaceutical Research And Development

Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.

Merck Research Laboratories

SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors.

Novartis Pharma

Mining the PDB for Tractable Cases Where X-ray Crystallography Combined with Fragment Screens Can Be Used to Systematically Design Protein-Protein Inhibitors: Two Test Cases Illustrated by IL1?-IL1R and p38?-TAB1 Complexes.

King'S College London

SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors.

Novartis Pharma